Across TCGA pan-cancer cohorts, RBM43 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated RBM43 data layer compared with 28 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher RBM43 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RBM43 expression acts as an unfavorable survival marker.

LUAD and COAD are the cancer types where RBM43 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	IV	0.342	0.893	<.001	20	view →
COAD	OS	Median	All	0.475	0.812	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

Exploration

Same gene, other analysis: RBM43 tumor-vs-normal RNA expression · all RBM43 data types